Biotechnology Industry
Filter News
Found 12,855 articles
-
Accenture recently published a new report, “New Science: Biopharma’s New Growth Machine.” In it, the report attempts to evaluate the last 20 years of trends in biopharma and use that data to develop projections for the future of the industry.
-
Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
4/25/2019
Investigator-initiated trial to evaluate AVID200’s safety, anti-fibrotic activity, and ability to restore hematopoiesis in patients with myelofibrosis
-
Gelesis Awarded $10.6 (€9.4) Million Grant to Support Commercial Manufacturing of PLENITY™
4/25/2019
PLENITY manufacturing facility will be the first factory to commercially produce medical super-absorbent hydrogels synthesized from naturally derived building blocks
-
The life sciences industry has seen significant growth over the past 10 years in Georgia. From 2007 to 2017, employment in the Peach State’s industry sciences grew by 14.9 percent. That growth outpaced the 7.7 percent national growth, Georgia Bio announced.
-
Expesicor and Novoron Bioscience Sign Collaboration Agreement to Develop Neuro-regenerative Compounds for Epilepsy, Alzheimer’s Disease, and ALS
4/24/2019
Expesicor announced an official collaboration agreement with Novoron Bioscience, a private, San Diego-based biotechnology company developing novel therapeutic approaches to address disorders of the central nervous system.
-
MilliporeSigma Introduces New Greener Solvent, Cyrene™
4/24/2019
New bio-derived product is a safer, more sustainable alternative for Dimethylformamide and N-Methyl-2-pyrrolidone solvents
-
EpiCypher® signs agreement with Thermo FIsher Scientific to deliver best-in-class ChIP-grade antibodies specific for histone PTMs
4/24/2019
EpiCypher® announced the signing of an agreement with Thermo Fisher Scientific, the world leader in servicing science, to provide co-exclusive use of EpiCypher’s SNAP-ChIP® technology.
-
Bicycle Therapeutics and Oxurion Announce Full Enrollment in Phase I Trial for the Treatment of Diabetic Macular Edema
4/24/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, and Oxurion today announced full enrollment of Oxurion’s Phase I trial designed to evaluate the safety of a single injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor.
-
CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences
4/24/2019
CytoSorbents Corporation shares highlights from the recent 6th International CytoSorb Users' Meeting and the Satellite Symposium at the 39th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium, and the 8th Annual EuroELSO 2019 Conference held recently in Barcelona, Spain.
-
United Therapeutics Corporation To Report First Quarter 2019 Financial Results Before The Market Opens On Wednesday, May 1, 2019
4/24/2019
United Therapeutics Corporation announced that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 1, 2019.
-
SkinTE Clinical Data to be Presented, PolarityTE to Host Booth and SkinTE Event at Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society Meeting
4/24/2019
PolarityTE, Inc., announced that new clinical data on the use of its SkinTE™ product will be presented at the Symposium on Advanced Wound Care Spring, Wound Healing Society meeting in San Antonio, TX from May 7 – 11, 2019.
-
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome
4/24/2019
Knopp Biosciences LLC announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome.
-
Macrogen and Exosome Plus to Jointly Develop Exosome-based Diagnostic and Treatment Solutions
4/24/2019
Contract signed for Macrogen to become the exclusive buyer of ‘Exosome Plus’ high-efficiency exosome isolation kit, ‘Exo2DTM’
-
Cavion to Present Results of Phase 2 Essential Tremor Clinical Trial in Platform Presentation at the American Academy of Neurology
4/24/2019
Presentation to provide overview of Phase 2 T-CALM study design, results and clinical path forward
-
Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Clinical Trial with Milciclib in Patients With Advanced Liver Cancer
4/24/2019
Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced results from the interim safety review conducted by the Independent Data Monitoring Committee (“IDMC”) on 21 March 2019.
-
EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology
4/24/2019
Patent protects EpimAb’s core technology FIT-Ig® and its entire bispecific pipeline with a broad composition of matter claim
-
TC BioPharm Initiates Phase I Trial of Allogeneic Gamma Delta T Cell Therapy in Acute Myeloid Leukemia Patients
4/24/2019
Study to provide safety data on allogeneic use of GDTs prior to subsequent use of CAR-modified variants
-
Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019
4/24/2019
Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET
-
Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumor-targeted Bispecific Bicycles at Peptides Congress
4/24/2019
Bicycle Therapeutics announced that Punit Upadhyaya, Ph.D., Senior Scientist at Bicycle, will present at the 6th Annual Peptides Congress in London.
-
BioCity invests in carbon recycling start-up, Deep Branch Biotechnology
4/24/2019
BioCity, a pioneering life science incubator and business collective, today announced investment in Deep Branch Biotechnology, a Nottingham-based carbon recycling start-up, developing technology that transforms polluters into producers.